A Clinical Study on the Safety and Efficacy of Wide-Band Ultrasound Combined With Traditional Chinese Medicine Preparations in the Prevention and Treatment of Keloids

ConditionKeloid
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age14-60
SponsorFujian Medical University Union Hospital

About this trial

The prevention and treatment of patients with multiple keloids throughout the body are extremely challenging. Keloids are highly resistant, refractory, and prone to recurrence, and are thus known as the "cancer that does not kill". At present, the main clinical strategy for such patients is staged surgical resection, followed by adjuvant local radiotherapy. When signs of recurrence appear, local injection of triamcinolone acetonide plus 5-fluorouracil (5-Fu) is administered as supplementary treatment. However, these two combination therapies have obvious limitations.

Adjuvant postoperative radiotherapy is associated with a high incidence of local skin adverse reactions, including radiodermatitis and delayed wound healing. Late complications may occur weeks or months after treatment, such as permanent hyperpigmentation and hypopigmentation, skin atrophy, fibrosis, scabbing and desquamation, and intractable ulcers. In addition, radiotherapy is not suitable for some young female patients and children when keloids are located near organs such as the thyroid gland and gonads.

Injection of triamcinolone acetonide plus 5-Fu causes significant pain and requires repeated sessions. Potential risks include local ulceration, hyperpigmentation, telangiectasia, and menstrual irregularities in female patients. Therefore, there is an urgent clinical need for a pathological scar prevention and treatment technique that can rapidly relieve discomfort, promote scar atrophy, cause no secondary injury, carry low risks, have a short recovery period, provide high comfort during treatment, and be applicable to large-area or multiple pathological scars across the body.

Our research team previously observed in clinical practice that wide-band ultrasound (Universal Beauty® Type I Ultrasound Therapeutic Device) combined with traditional Chinese medicine (TCM) preparations can release abnormally accumulated and contracted collagen fibers in scar tissue via ultrasonic energy. Meanwhile, ultrasound promotes the penetration of TCM into scar lesions, exerting effects of infection control, inflammation inhibition, subsidence of redness and swelling, and relief of itching and pain.

Compared with conventional scar therapies, this approach achieves rapid symptom control, no secondary damage, no obvious side effects, a short recovery period, and high treatment comfort. It shows particularly significant advantages for large-area or multiple pathological scars throughout the body that are difficult to treat with traditional methods. Preliminary treatment in a small number of volunteers with multiple keloids has achieved satisfactory outcomes without obvious adverse reactions.

The purpose of this study is to verify the efficacy and safety of wide-band ultrasound combined with TCM preparation (Chuang Li Fu) in the prevention and treatment of keloids through this clinical trial.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Wide-Band Ultrasound

    Device

    The ultrasound probe is placed over the gauze during treatment.

  • traditional Chinese medicine

    Drug

    Gauze saturated with TCM preparation is applied onto the keloid lesion

Treatment groups

120 Participants
are divided into 4 treatment groups
Group A: Blank control group (Group 0#)No intervention 0 interventions
Group B: Ultrasound + TCM preparation group (Group 1#)Experimental treatment 2 interventions
Group C: Ultrasound + normal saline group (Group 2#)Experimental treatment 1 intervention
Group D: TCM gauze external application alone group (Group 3#)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Vancouver Scar Scale (VSS)

① After the first stage: the improvement in the experimental group was at least 2 points greater than that in the control group, with statistical significance.② At follow-up endpoint: no obvious hypertrophic growth in any incision scar.

Time frame
up to 3 months
2

Patient and Observer Scar Assessment Scale (POSAS)

① At the end of Stage 1: The improvement in the experimental group was at least 6 points greater than that in the control group, with statistical significance. In addition, the three sub-items (vascularity, itching, pain) each improved by at least 2 points, with statistical significance. ② At follow-up endpoint: No obvious hypertrophic proliferation was observed in any incision scar.

Time frame
up to 3 months
3

Scar height above the surrounding skin

① At the end of Stage 1: The scar height in the experimental group was lower than that in the control group, with statistical significance.② At follow-up endpoint: No obvious hypertrophic proliferation was observed in any incision scar.

Time frame
up to 3 months
4

Number and proportion of scar recurrence and hypertrophy

At follow-up endpoint, incisional recurrence rate will be lower than the 20% minimum recurrence rate of postoperative radiotherapy reported in literature.

Time frame
through study completion , an average 1.5 year

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: